First human test of new drug for HPV cancers begins
NCT ID NCT05976828
Summary
This is an early safety study to find the highest safe dose and identify side effects of an experimental drug called IBRX-042 for people with HPV-related cancers that have returned or progressed. It will involve about 12 participants who have already tried standard treatments. The main goal is to understand how the body handles the drug, given as three injections over nine weeks, before testing if it effectively fights cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chan Soon-Shiong Institute for Medicine (CSSIFM)
El Segundo, California, 90245, United States
-
Texas Oncology Austin Central
Austin, Texas, 78731, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.